1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 29, 24/Jul/2025
  4. Article
Surveillance Open Access
Like 0
Download

SDG 3: hepatitis

Abstract

BACKGROUND

Hepatitis C virus (HCV) microelimination among at-risk migrants supports global elimination goals.

AIM

To evaluate risk factors, prevalence and trends of active HCV infection among at-risk migrants screened for HCV in Madrid from 2019–23.

METHODS

At-risk migrants (born outside Spain, living in country < 10 years regardless of legal status), were screened for HCV via mobile units with rapid antibody testing, and confirmed by RNA testing. Recruitment of this convenience sample focused on migrant centres, shelters, harm reduction centres and social service sites. Primary outcome was active HCV prevalence. Risk factors analysed included origin, alcohol use, no stable income, drug use and sexual behaviour. Data were analysed using general linear models with negative binomial distribution and p values adjusted for multiple comparisons (q values).

RESULTS

Among 2,288 migrants, 6.5% (149/2,288) had anti-HCV antibodies, 47.0% (70/149) of whom tested positive for HCV-RNA; 81.4% (57/70) began antiviral therapy. Overall prevalence of active HCV infection was 3.1% (70/2,288). Injection drug use (non-active vs never used (aIRR: 7.3; 95% CI: 2.7–12.7) and active (aIRR: 14.7; 95% CI: 6.7–32.1)), European origin (vs non-European; aIRR: 5.8; 95% CI:  2.7–12.7) and alcohol misuse (vs no misuse; aIRR: 1.8; 95% CI: 1.1–2.9) were main risk factors. Prevalence showed no significant change during 2019–23 in the overall population and across risk groups.

CONCLUSION

At-risk migrants screened in Madrid had a high prevalence of active HCV infection. This is higher than reported estimates for the general Spanish population and supports the need to enhance targeted HCV prevention, screening and treatment strategies among migrant populations.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.29.2500150
2025-07-24
2025-07-26
/content/10.2807/1560-7917.ES.2025.30.29.2500150
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/29/eurosurv-30-29-1.html?itemId=/content/10.2807/1560-7917.ES.2025.30.29.2500150&mimeType=html&fmt=ahah

References

  1. Martinello M, Solomon SS, Terrault NA, Dore GJ, Hepatitis C. Hepatitis C. Lancet. 2023;402(10407):1085-96.  https://doi.org/10.1016/S0140-6736(23)01320-X  PMID: 37741678 
  2. Bhattacharya D, Aronsohn A, Price J, Lo Re V, AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2023;ciad319.  https://doi.org/10.1093/cid/ciad319  PMID: 37229695 
  3. Gamkrelidze I, Pawlotsky JM, Lazarus JV, Feld JJ, Zeuzem S, Bao Y, et al. Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. Liver Int. 2021;41(3):456-63.  https://doi.org/10.1111/liv.14779  PMID: 33389788 
  4. Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4(2):135-84.  https://doi.org/10.1016/S2468-1253(18)30270-X  PMID: 30647010 
  5. World Health Organization (WHO). Hepatitis C, 2024. Geneva: WHO; 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
  6. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1) Suppl;S45-57.  https://doi.org/10.1016/j.jhep.2014.07.027  PMID: 25086286 
  7. Estirado Gómez A, Justo Gil S, Limia A, Avellón A, Arce Arnáez A, González-Rubio R, et al. Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey. Eur J Public Health. 2021;31(6):1117-22.  https://doi.org/10.1016/j.jhep.2014.07.027  PMID: 25086286 
  8. Office of the Secretary for Health and Consumer Affairs. Strategic plan for tackling hepatitis C in the Spanish National Health System p. 1-94. Madrid: Ministry of Health, Social Services and Equality; 2015. Available from: https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/PEAHC_eng.pdf
  9. Lens S, Miralpeix A, Gálvez M, Martró E, González N, Rodríguez-Tajes S, et al. HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates. JHEP Rep Innov Hepatol. 2022;4(12):100580.  https://doi.org/10.1016/j.jhepr.2022.100580  PMID: 36316992 
  10. Cabezas J, Llerena S, Mateo M, Álvarez R, Cobo C, González V, et al. Hepatitis C micro-elimination beyond prison walls: navigator-assisted test-and-treat strategy for subjects serving non-custodial sentences. Diagnostics (Basel). 2021;11(5):877.  https://doi.org/10.3390/diagnostics11050877  PMID: 34068955 
  11. Ryan P, Valencia J, Sepulveda-Crespo D, Amigot-Sanchez R, Cuevas G, Lazarus JV, et al. Prevalence of hepatitis C infection among people experiencing homelessness between 2019-2023 in Madrid, Spain. JAMA Netw Open. 2024. Forthcoming.
  12. Ryan P, Valencia J, Cuevas G, Amigot-Sanchez R, Martínez I, Lazarus JV, et al. Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study. Euro Surveill. 2024;29(29):2300712.  https://doi.org/10.2807/1560-7917.ES.2024.29.29.2300712  PMID: 39027941 
  13. Falla AM, Ahmad AA, Duffell E, Noori T, Veldhuijzen IK. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries. BMC Infect Dis. 2018;18(1):42.  https://doi.org/10.1186/s12879-017-2908-5  PMID: 29338702 
  14. European Centre for Disease Prevention and Control (ECDC). Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA, 2016. Stockholm: ECDC; 2016. Available from: https://www.ecdc.europa.eu/en/publications-data/epidemiological-assessment-hepatitis-b-and-c-among-migrants-eueea
  15. Lazarus JV, Bromberg DJ, Del Amo J, Norgaard O, García-Samaniego J, Casellas A, et al. Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. Enferm Infecc Microbiol Clin (Engl Ed). 2019;37(4):222-30.  https://doi.org/10.1016/j.eimce.2018.04.021  PMID: 29759423 
  16. Ryan P, Valencia J, Cuevas G, Torres-Macho J, Troya J, Pueyo Á, et al. Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain. Int J Drug Policy. 2021;96:103424.  https://doi.org/10.1016/j.drugpo.2021.103424  PMID: 34429222 
  17. Folch C, Saludes V, Reyes-Ureña J, Antuori A, Ibáñez N, Majó X, et al. The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: Major gaps for migrants. Int J Drug Policy. 2021;90:103057.  https://doi.org/10.1016/j.drugpo.2020.103057  PMID: 33310634 
  18. Derks L, Gassowski M, Nielsen S, An der Heiden M, Bannert N, Bock CT, et al. Risk behaviours and viral infections among drug injecting migrants from the former Soviet Union in Germany: Results from the DRUCK-study. Int J Drug Policy. 2018;59:54-62.  https://doi.org/10.1016/j.drugpo.2018.06.011  PMID: 30005420 
  19. Instituto Nacional de Estadística (INE). Continuous Population Statistics (CPS), 1 April, 2024. Provisional data. Madrid: INE; 2023. Available from: https://www.ine.es/dyngs/Prensa/en/ECP1T24.htm
  20. Moonen CPB, den Heijer CDJ, Dukers-Muijrers NHTM, van Dreumel R, Steins SCJ, Hoebe CJPA. A systematic review of barriers and facilitators for hepatitis B and C screening among migrants in the EU/EEA region. Front Public Health. 2023;11:1118227.  https://doi.org/10.3389/fpubh.2023.1118227  PMID: 36875381 
  21. Yela E, Solé N, Puig L, López Gallegos D, Clua-García R. Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting. Harm Reduct J. 2024;21(1):88.  https://doi.org/10.1186/s12954-024-01009-7  PMID: 38678266 
  22. Ryan P, Manzano S, Deihim-Rahampour N, Cuevas G, Martin-Gonzalez L, Gonzalez-Baeza A, et al. HIV-infected Latin American asylum seekers in Madrid, Spain, 2022: A prospective cohort study from a major gateway in Europe. Euro Surveill. 2024;29(29):2300692.  https://doi.org/10.2807/1560-7917.ES.2024.29.29.2300692  PMID: 39027943 
  23. Lebano A, Hamed S, Bradby H, Gil-Salmerón A, Durá-Ferrandis E, Garcés-Ferrer J, et al. Migrants’ and refugees’ health status and healthcare in Europe: a scoping literature review. BMC Public Health. 2020;20(1):1039.  https://doi.org/10.1186/s12889-020-08749-8  PMID: 32605605 
  24. Mirzoyan L, Berendes S, Jeffery C, Thomson J, Ben Othman H, Danon L, et al. New evidence on the HIV epidemic in Libya: why countries must implement prevention programs among people who inject drugs. J Acquir Immune Defic Syndr. 2013;62(5):577-83.  https://doi.org/10.1097/QAI.0b013e318284714a  PMID: 23337363 
  25. Melo JS, Mittal ML, Horyniak D, Strathdee SA, Werb D. Injection Drug Use Trajectories among Migrant Populations: A Narrative Review. Subst Use Misuse. 2018;53(9):1558-70.  https://doi.org/10.1080/10826084.2017.1416404  PMID: 29364762 
  26. De La Mora L, Laguno M, De Lazzari E, Ugarte A, Leal L, Torres B, et al. Vulnerability conditions in a cohort of men who have sex with men who engage in chemsex in Barcelona city: a cross-sectional study. Sex Res Soc Policy. 2023;20(2):614-25.  https://doi.org/10.1007/s13178-022-00702-1 
  27. Duracinsky M, Yaya I, Yombo-Kokule L, Bessonneau P, Thonon F, Rousset-Torrente O, et al. Development of a risk prediction score for screening for HBV, HCV and HIV among migrants in France: results from a multicentre observational study (STRADA study). BMJ Open. 2024;14(6):e075315.  https://doi.org/10.1136/bmjopen-2023-075315  PMID: 38839381 
  28. Jakab Z, Severoni S, Ostlin P, Verschuuren M, Stein CE. Refugee and migrant health: a priority in the WHO European Region. Lancet. 2015;386(10012):2477-8.  https://doi.org/10.1016/S0140-6736(15)01102-2  PMID: 26738713 
  29. Baggaley RF, Nazareth J, Divall P, Pan D, Martin CA, Volik M, et al. National policies for delivering tuberculosis, HIV and hepatitis B and C virus infection services for refugees and migrants among Member States of the WHO European Region. J Travel Med. 2023;30(1):taac136.  https://doi.org/10.1093/jtm/taac136  PMID: 36426801 
  30. Sagnelli E, Alessio L, Sagnelli C, Gualdieri L, Pisaturo M, Minichini C, et al. Clinical Findings of HCV chronic infection in undocumented immigrants and low-income refugees in three areas of southern Italy. Ann Hepatol. 2018;17(1):47-53.  https://doi.org/10.5604/01.3001.0010.7534  PMID: 29311411 
  31. Coppola N, Alessio L, De Pascalis S, Macera M, Di Caprio G, Messina V, et al. Effectiveness of test-and-treat model with direct-acting antiviral for hepatitis C virus infection in migrants: a prospective interventional study in Italy. Infect Dis Poverty. 2024;13(1):39.  https://doi.org/10.1186/s40249-024-01200-9  PMID: 38802954 
  32. Buonfrate D, Gobbi F, Marchese V, Postiglione C, Badona Monteiro G, Giorli G, et al. Extended screening for infectious diseases among newly-arrived asylum seekers from Africa and Asia, Verona province, Italy, April 2014 to June 2015. Euro Surveill. 2018;23(16):17-00527.  https://doi.org/10.2807/1560-7917.ES.2018.23.16.17-00527  PMID: 29692316 
  33. Dugan E, Blach S, Biondi M, Cai Z, DePaola M, Estes C, et al. Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. Lancet Gastroenterol Hepatol. 2021;6(3):169-84.  https://doi.org/10.1016/S2468-1253(20)30359-9  PMID: 33515496 
  34. Greenaway C, Azoulay L, Allard R, Cox J, Tran VA, Abou Chakra CN, et al. A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada. BMC Infect Dis. 2017;17(1):140.  https://doi.org/10.1186/s12879-017-2242-y  PMID: 28193199 
  35. Quaranta MG, Ferrigno L, Tata X, D’Angelo F, Massari M, Coppola C, et al. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Dig Liver Dis. 2021;53(12):1603-9.  https://doi.org/10.1016/j.dld.2021.03.020  PMID: 33893040 
  36. Valencia J, Lazarus JV, Ceballos FC, Troya J, Cuevas G, Resino S, et al. Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care. Liver Int. 2022;42(2):309-19.  https://doi.org/10.1111/liv.15095  PMID: 34767680 
  37. Blach S, Terrault NA, Tacke F, Gamkrelidze I, Craxi A, Tanaka J, et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396-415.  https://doi.org/10.1016/S2468-1253(21)00472-6  PMID: 35180382 
  38. Ortiz E, Scanlon B, Mullens A, Durham J. Effectiveness of interventions for hepatitis B and C: a systematic review of vaccination, screening, health promotion and linkage to care within higher income countries. J Community Health. 2020;45(1):201-18.  https://doi.org/10.1007/s10900-019-00699-6  PMID: 31332639 
  39. Djaogol T, Fontaine H, Baudoin M, Protopopescu C, Marcellin F, Dorival C, et al. Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France. Liver Int. 2021;41(10):2328-40.  https://doi.org/10.1111/liv.14823  PMID: 33590608 
  40. Coppola N, Alessio L, Gualdieri L, Pisaturo M, Sagnelli C, Caprio N, et al. Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013. Euro Surveill. 2015;20(35):30009.  https://doi.org/10.2807/1560-7917.ES.2015.20.35.30009  PMID: 26530499 
  41. Bil JP, Schrooders PA, Prins M, Kouw PM, Klomp JH, Scholing M, et al. Integrating hepatitis B, hepatitis C and HIV screening into tuberculosis entry screening for migrants in the Netherlands, 2013 to 2015. Euro Surveill. 2018;23(11):17-00491.  https://doi.org/10.2807/1560-7917.ES.2018.23.11.17-00491  PMID: 29560855 
  42. Klok S, van Dulm E, Boyd A, Generaal E, Eskander S, Joore IK, et al. Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections among undocumented migrants and uninsured legal residents in the Netherlands: A cross-sectional study, 2018-2019. PLoS One. 2021;16(10):e0258932.  https://doi.org/10.1371/journal.pone.0258932  PMID: 34714867 
  43. Jablonka A, Solbach P, Wöbse M, Manns MP, Schmidt RE, Wedemeyer H, et al. Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015. Eur J Gastroenterol Hepatol. 2017;29(8):939-45.  https://doi.org/10.1097/MEG.0000000000000889  PMID: 28492419 
  44. Rosa-Hezode I, Chousterman M, Costes L, Labourdette C, Elghozi B, Krastinova E, et al. Cascade of care for migrants tested Hepatitis C antibodies positive in France through a systematic screening programme: The PRECAVIR study. J Viral Hepat. 2019;26(12):1496-9.  https://doi.org/10.1111/jvh.13192  PMID: 31433886 
  45. Prestileo T, Di Marco V, Dino O, Sanfilippo A, Tutone M, Milesi M, et al. Effectiveness of a screening program for HBV, HCV, and HIV infections in African migrants to Sicily. Dig Liver Dis. 2022;54(6):800-4.  https://doi.org/10.1016/j.dld.2021.08.024  PMID: 34649829 
  46. Martró E, Ouaarab H, Saludes V, Buti M, Treviño B, Roade L, et al. Pilot hepatitis C micro-elimination strategy in Pakistani migrants in Catalonia through a community intervention. Liver Int. 2022;42(8):1751-61.  https://doi.org/10.1111/liv.15327  PMID: 35635535 
Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Pablo+Ryan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ryan Pablo</a>, <a href="/search?value1=Jorge+Valencia&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Valencia Jorge</a>, <a href="/search?value1=Felipe+P%C3%A9rez-Garc%C3%ADa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pérez-García Felipe</a>, <a href="/search?value1=Marta+Quero-Delgado&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Quero-Delgado Marta</a>, <a href="/search?value1=Guillermo+Cuevas&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cuevas Guillermo</a>, <a href="/search?value1=Samuel+Manzano&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Manzano Samuel</a>, <a href="/search?value1=Samuel+Est%C3%A9vez&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Estévez Samuel</a>, <a href="/search?value1=Isidoro+Mart%C3%ADnez&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martínez Isidoro</a>, <a href="/search?value1=Daniel+Sep%C3%BAlveda-Crespo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sepúlveda-Crespo Daniel</a>, <a href="/search?value1=Salvador+Resino&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Resino Salvador</a></span>. Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(29):pii=2500150. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.29.2500150" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.29.2500150</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 28 Feb 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 03 Jun 2025 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.29.2500150
/content/10.2807/1560-7917.ES.2025.30.29.2500150
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error